Bausch Health Cos., Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CA0717341071
CAD
10.32
0.47 (4.77%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Bausch Health Cos., Inc. stock-summary
stock-summary
Bausch Health Cos., Inc.
Pharmaceuticals & Biotechnology
Bausch Health Companies Inc, formerly Valeant Pharmaceuticals International Inc, is a Canada-based company that develops, manufactures and markets a range of branded and generic pharmaceuticals, medical devices and over-the-counter products. It primarily develops products in the therapeutic areas of eye health, gastroenterology and dermatology. Its dermatology products treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis and other dermatoses. It also offers a selection of aesthetic medical devices that address a variety of conditions, including facial wrinkles, acne, pigmentation conditions and laser hair removal, among others. The gastrointestinal (GI) segment offers products that treat GI and hepatologic conditions, including hepatic encephalopathy, irritable bowel syndrome with diarrhea and ulcerative colitis, among others. Its eye health products are marketed in the following categories: Contact Lens, Pharmaceutical Products and Surgical.
Company Coordinates stock-summary
Company Details
2150 Saint-Elzear Blvd W , LAVAL QC : H7L 4A8
stock-summary
Tel: 1 514 74467921 949 4616002
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 16 Schemes (2.63%)

Foreign Institutions

Held by 436 Foreign Institutions (56.93%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Joseph Papa
Chairman of the Board, Chief Executive Officer
Mr. Thomas Ross
Lead Independent Director
Mr. Richard De Schutter
Independent Director
Mr. D. Robert Hale
Independent Director
Dr. Argeris Karabelas
Independent Director
Ms. Sarah Kavanagh
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

CAD 3,900 Million ()

stock-summary
P/E

16.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-18.35

stock-summary
Return on Equity

1.10%

stock-summary
Price to Book

-3.31